drugset / Trial / NCT00545675

Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness

NCT00545675

Phase 4 Completed 146 enrolled Korea Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To demonstrate the difference between Abilify with Depakote vs. Placebo with Depakote in 24-week treatment in patients with remission status after Abilify with Depakote in the 6-week study of acute mania in patients with bipolar disorder

Timeline

Start
2007-12
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified
Comparator Divalproex Sodium Small molecule

Indications